FundRx

FundRx, Inc. is a New York-based venture capital firm established in 2015 that focuses on early-stage investments in the healthcare and life sciences sectors. The firm specializes in various subfields, including pharmaceuticals, medical devices, biotechnology, diagnostics, healthcare IT, and healthcare services. FundRx primarily targets companies located in the United States, Canada, the United Kingdom, and Israel, though it may consider opportunities in other regions. The firm typically invests a minimum of $20,000 and seeks to take a 20% carried interest on successful exits from its investments.

Ruchi Dana

Venture Partner

9 past transactions

Lucy Goods

Series A in 2020
Lucy Goods, Inc. is a company based in Los Angeles, California, that specializes in manufacturing and selling nicotine alternatives, primarily in the form of gum and lozenges. Established in 2016, the company aims to reduce tobacco-related harm by offering next-generation nicotine products made with pure nicotine and food-grade ingredients. Lucy Goods provides its products in various flavors, including fruit, mint, and cinnamon, catering to consumer preferences. The company markets its products primarily online, positioning itself as a cleaner and more convenient alternative to conventional tobacco products.

CloudCath

Series A in 2020
CloudCath is a company that specializes in developing a remote monitoring platform for peritoneal dialysis patients. Their innovative system utilizes sensor-enabled technology to provide continuous monitoring, allowing for early detection of complications associated with catheter-based treatments. By leveraging Internet of Things (IoT) capabilities, CloudCath's platform enables healthcare providers to remotely oversee patients during their home treatment, significantly reducing the frequency of in-person visits. This approach not only enhances patient safety but also improves the overall management of care for individuals undergoing peritoneal dialysis, ultimately promoting better health outcomes.

ixlayer

Series A in 2019
ixlayer enables leading health systems, clinical labs, biopharma, and consumer companies to offer precision health testing, by remove all the technical, security, and regulatory complexity involved in launching a clinical health test.

Osmosis

Series A in 2019
Osmosis is a personalized learning platform focused on enhancing health education by providing a deeper understanding of medical concepts. The platform enables clinicians and caregivers to access a wealth of educational resources, including a comprehensive library of videos and multiple-choice questions. Driven by data and technology, Osmosis aims to improve retention and preparedness for courses and exams, making it a valuable tool for medical professionals seeking to deepen their knowledge and skills in the healthcare field. By offering tailored content that goes beyond traditional lectures, Osmosis supports effective learning for a global audience in the medical community.

Mightier

Series A in 2019
Mightier is a gaming platform designed to assist children in regulating their emotions through scientifically-backed methods. Founded in 2016 and based in Boston, Massachusetts, the platform features bioresponsive video games developed in collaboration with Boston Children's Hospital and Harvard Medical School. The games utilize a biofeedback heart rate monitor that adjusts the difficulty level based on the player's emotional state, helping children learn to manage their feelings in real-time. By engaging with these interactive experiences, children with behavioral and emotional challenges can discover their emotional strengths and develop skills to harness their emotions in everyday situations.

Contraline

Seed Round in 2018
Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company has created Echo-V, an ultrasound-visible polymer solution that is injected into the vas deferens, forming a semi-permeable hydrogel device that blocks sperm while allowing bodily fluids to pass through. This product is part of a non-surgical procedure known as Vasintomy. Contraline's first product, Adam, utilizes a proprietary injectable hydrogel platform and is designed for a minimally invasive outpatient procedure. Adam is non-hormonal, intended to provide effective contraception for several years, and can be easily reversed. Established in 2015, Contraline aims to advance reproductive health through its unique approaches to male contraception.

Wellth

Seed Round in 2018
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.

Buoy Health

Series A in 2017
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Sonavex

Series A in 2017
Sonavex, Inc. is a Baltimore-based company founded in 2013 that specializes in advanced imaging technology for surgical patients. The company's primary focus is on developing an ultrasound-based method to detect anastomotic blood clots, which are critical for patient recovery post-surgery. By providing clinicians with real-time visualization of essential data directly at the point of care, Sonavex aims to enhance clinical decision-making and improve patient outcomes. Their proprietary technology platform allows for the measurement of crucial intravascular flow metrics, enabling the early detection of post-operative clots and contributing to better overall surgical results.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.